# Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

> **NCT04552223** · PHASE2 · COMPLETED · sponsor: **Jose Lutzky, MD** · enrollment: 27 (actual)

## Conditions studied

- Metastatic Uveal Melanoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Relatlimab

## Key facts

- **NCT ID:** NCT04552223
- **Lead sponsor:** Jose Lutzky, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-10
- **Primary completion:** 2024-01-04
- **Final completion:** 2026-01-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04552223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04552223, "Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT04552223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*